Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medicating the obese patient

D H Ryan1

  • 1Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, USA.

Endocrinology and Metabolism Clinics of North America
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.

Obesity pillars·2026
Same author

Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: Prespecified and exploratory analysis of the Epitomee capsule RESET study.

Obesity pillars·2025
Same author

The magnetic structure and spin-reorientation of ErGa.

Acta crystallographica Section B, Structural science, crystal engineering and materials·2024
Same author

Magnetic crystalline-symmetry-protected axion electrodynamics and field-tunable unpinned Dirac cones in EuIn<sub>2</sub>As<sub>2</sub>.

Nature communications·2021
Same author

Efficacy and safety of an oral device to reduce food intake and promote weight loss.

Obesity science & practice·2018
Same author

Magnetic properties of Ln<sub>2</sub>CoGe<sub>4</sub>O<sub>12</sub> and LnBCoGe<sub>4</sub>O<sub>12</sub> (Ln = Gd, Tb, Dy, Ho, Er; B = Sc, Lu).

Dalton transactions (Cambridge, England : 2003)·2017
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Medications are increasingly accepted for obesity treatment, complementing diet and behavior changes. Clinical judgment guides prescribing based on patient factors and available FDA-approved or investigational drugs.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Public Health

Background:

  • Obesity treatment traditionally relies on diet and behavior modification.
  • Advances in understanding body weight regulation support pharmacologic interventions.
  • A pharmacobehavioral approach demonstrates effective chronic weight loss maintenance.

Purpose of the Study:

  • To review the current status and future directions of pharmacotherapy for obesity.
  • To highlight the role of clinical judgment in medication selection for obesity.
  • To discuss FDA-approved and investigational agents for weight management.

Main Methods:

  • Review of current literature on obesity pharmacotherapy.
  • Discussion of factors influencing medication decisions (BMI, comorbidities, etc.).

Related Experiment Videos

  • Overview of approved and unapproved weight loss medications.

    • Main Results:

    • Several nonadrenergic and one serotonergic agent are FDA-approved for weight loss.
    • Over-the-counter phenylpropanolamine is available.
    • Fluoxetine, ephedrine, and caffeine show efficacy in trials but lack FDA obesity indications.

    Conclusions:

    • Medication is an emerging, legitimate adjunct to diet and behavior modification for obesity.
    • Clinical judgment is crucial for selecting appropriate pharmacotherapy.
    • Combination therapy and adjunctive use with lifestyle interventions are key research areas.